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Buyang Huanwu Decoction (BYHWD) is a well-known Chinese medicine formula. Recent studies have reported that BYHWD
can be used to treat ischemic heart disease. This study investigated the potential mechanism underlying the roles of BYHWD
in alleviating the myocardial ischemia induced by isoproterenol (ISO) in rats. Diﬀerent doses of BYHWD (25.68, 12.84 and
6.42gkg−1) were lavaged to rats, respectively. Then the expression of the cluster of diﬀerentiation 40 (CD40) in the mononuclear
cells was measured using ﬂow cytometry, and the expressions of CD40 and its ligand (CD40L) in myocardial tissues were
determined by western blotting. The serum biochemical values of superoxide dismutase (SOD) activity, the malondialdehyde
(MDA) level and the free fatty acid (FFA) content were measured. The results showed that the SOD activities of BYHWD groups
were signiﬁcantly higher than that of the ISO group, while the MDA levels and FFA contents of all BYHWD groups were lower
than that of the ISO group. BYHWD could decrease the expression of CD40 in the mononuclear cells and the CD40 and CD40L
expressions in myocardial tissues. Our data suggest that the roles of BYHWD are not only related to its antioxidative action and
regulationoflipidmetabolisms,butalsototheinhibitionofinﬂammatorypathwayby thedecreased CD40andCD40Lexpressions
in rats with myocardial ischemia.
1.Introduction
Ischemic heart disease (IHD), one of the leading chronic
disorders, is often highlighted in public health [1]. In recent
years, inﬂammation has been recognized as a major driving
force in ischemic process, and increasing evidencehas shown
that enhanced levels of inﬂammatory markers, including C-
reactive protein, NF-kappa B and matrix metalloproteinases,
are related to IHD [2–4]. During the past decade, the cluster
of diﬀerentiation 40 (CD40) and its ligand (CD40L), as
important inﬂammatory regulators, have been found to
play a role in atherosclerosis [5]. Studies have revealed that
CD40/CD40L plays an important role in IHD and that the
inhibitionofCD40/CD40Lmay be used asa new therapeutic
strategy for IHD treatment [6].
Buyang Huanwu Decoction (BYHWD), a well-known
Chinese medicine formula, has been extensively used for
improving neurological functional recovery in stroke-in-
duced disability in China for centuries. Few recent studies
have reported that BYHWD can be used to treat ischemic
coronary heart disease by relieving angina pectoris [7, 8].
Investigations have showed that BYHWD has the capacity to
inhibit inﬂammatory pathway in rats with cerebral ischemia
and in stroke patients [9, 10]. Nevertheless, little is known
about the mechanism by which BYHWD alleviates IHD.
In the previous study, we have found that BYHWD cannot
only improve the electrocardiogram of rats with myocardial
ischemia, but also decrease the activities of lactate dehy-
drogenase, creatine kinase and aspartate aminotransferase,
which are related to the inhibition of isoproterenol (ISO)-
induced nitric oxide synthase in rats [11]. ISO induces
alterations in membrane permeability, resulting in the loss
of function and integrity of myocardial membranes at
dosages exceeding the physiological concentrations [12]. To2 Evidence-Based Complementary and Alternative Medicine
further research the potential mechanism of BYHWD, the
present study examined the expression of CD40 in the
mononuclear cells, the expressions of CD40 and CD40L
in myocardial tissues, the superoxide dismutase (SOD)
activity, malondialdehyde (MDA) level and the content
of free fatty acid (FFA) in the serum to assess the roles
of the BYHWD in anti-inﬂammation, antioxidation and
regulation of lipid metabolisms in the myocardial ischemic
rats.
2.Methods
2.1. Materials. Trihydroxymethyl aminomethane (Tris),
glycine, sodium dodecyl sulfate (SDS), acrylamide and
bis-acrylamide were purchased from Amresco (Amresco,
USA). Anti-CD40, anti-CD40L antibody and anti-β-actin
antibody were obtained from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Goat anti-rabbit horseradish
peroxidase-linked antibody, BCA Protein Assay kit, Mem-
PER Eukaryotic Membrane Protein Extraction Reagent
Kit, BlueRanger Prestained Protein Molecular Weight
Marker Mix and SuperSignal West Pico Chemiluminescent
Substrate were obtained from Pierce Chemical Company
(Pierce, USA). Goat anti-rabbit FITC-conjugated IgG
antibody was purchased from Jackson immunoresearch
(Jackson, USA). SOD, FFA and MDA assay kits were
produced by the Institute of Nanjing Jiancheng Biology
Engineering (Nanjing, P. R. China). Protein Extraction
Reagent(RIPA) kit was purchased from BiotekeCorporation
( B e i j i n g ,P .R .C h i n a ) .I S Ow a sp u r c h a s e df r o mS i g m a
Biotechnology (Sigma, USA). Compound Danshen
Dropping Pills (CDDP) was obtained from Tianjin Tianshili
Pharmaceuticals Company (Tianjin, P. R. China). All other
agents used in the study were of the commercially available
grade.
2.2. Preparation of BYHWD. BYHWD was made from seven
medicinal components: 120g milkvetch root, 6g Chinese
angelica, 3g Szechwan lovage rhizome, 4.5g red peony
r o o t ,3ge a r t hw o r m ,3gp e a c hs e e da n d3gs a ﬄower. The
seven crude drugs were purchased from Xi’an pharmacy
of Beijing Tongrentang and authenticated by experts in
pharmacognosy. The mixture of the crude drugs was soaked
in distilled water and boiled twice [13]. The resulted
BYHWD was ﬁltered through a mesh, and the ﬁltrate was
concentrated to 3gmL−1 by a vacuum pump and stored at
4◦C until use. CDDP was used here as a positive control
drug. The major ingredient of CDDP is Danshen. Danshen
is an important traditional Chinese herbal medicine that
has extensiveclinicalapplicationsforcardiovascular diseases,
including acute myocardial infarction [14].
2.3. Experimental Animals and Model. The experiments
were performed on 60 male adult Sprague-Dawley (SD)
rats, each weighing 180–200g, provided by Medical Exper-
imental Animal Center of the Xi’an Jiaotong University
(Xi’an, China). Animals were randomly allocated to six
equal number groups: control, ISO, pre-treatment with
CDDP (0.073gkg−1) and three pre-treatment with BYHWD
(25.68, 12.84 and 6.42gkg−1, resp.). ISO-induced myocar-
dial ischemic animal model was established by intraperi-
toneal injection of ISO (0.03gkg−1)o n c ead a yf o r3d a y s
[15, 16]. Under anesthesia condition, if electrocardiogram
recording indicated a signiﬁcant ST segment fall of >0.lmV,
it was considered that this myocardial ischemia model has
been established, as reported previously [11]. It is clinically
important if ST segment elevated or fell as it can be a sign of
ischemia and hyperkalemia.
Rats in BYHWD and CDDP groups were intragastrically
administered with BYHWD and CDDP, respectively, once a
day for 14 days. From day 12, ISO was injected to all the
animals except those in the control group. By the end of
day 14, rats were anesthetized with pentobarbital sodium,
and heart tissue and bloodsamples were collected for further
examinations. The experimental protocol was in accordance
withtheNationalInstitutesofHealthGuideforCareandUse
ofLaboratory Animals and was approvedby the Institutional
Animal Care Committee of Xi’an Jiaotong University.
2.4. CD40 Expression in Mononuclear Cells. The expression
of CD40 in the mononuclear cells was measured using ﬂow
cytometry, as previously described [17]. Brieﬂy, heparin
was added into the collected blood, and then the heparin-
anticoagulated blood was incubated with the rabbit anti-rat
CD40 polyclone antibody for 30min at room temperature
(RT), washed twice with phosphate buﬀered saline (PBS, pH
7.4) and centrifuged at 1000g for 3min before incubating
with the goat anti-rabbit FITC-conjugated IgG for 30min at
RT.Finally,thebloodsoderivedwasimmediately ﬁxedin4%
paraformaldehyde PBS and analyzed for the determination
of the CD40 expression in mononuclear cells using a
Becton Dickinson FACScan ﬂow cytometry (BD Biosciences,
USA).
2.5. CD40 and CD40L Expressions in Myocardial Tissues.
To investigate the potential mechanisms by which BYHYD
protects myocardium from ischemia, the expressions of
CD40 and CD40L in myocardial tissues were determined by
western blotting. Membrane protein of myocardial tissues
was extracted following the instructions of the Mem-
PER Eukaryotic Membrane Protein Extraction Reagent Kit.
Protein concentration was quantiﬁed using a BCA pro-
tein quantity assay kit before 12% sodium dodecyl sul-
fate polyacrylamide gel electrophoresis (SDS-PAGE) under
4◦C. Then the protein was transferred onto microp-
orous polyvinylidene ﬂuoride membranes in running buﬀer
containing 20% methanol. After non-speciﬁc sites were
blockedwith 5%milk-Tris buﬀeredsaline-Tween 20(TBST),
the membranes were incubated with anti-CD40 antibody,
anti-CD40L antibody and anti-β-actin antibody overnight,
respectively. Then, a horseradish peroxidase-linked antibody
was employed as a secondary antibody after the membranes
were washed in TBST. The bands of interest were detected
using an enhanced chemiluminescent technique. Densities
of the bands were measured using an IBAS ReL2.0 image
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2.6. SOD Activity and MDA Level in Serum. SOD activity
and MDA level in the serum were measured as previously
described [18]. In brief, when rats were sacriﬁced, blood was
collected and centrifuged at 800g for 5min; then the serum
was collected for the detection of SOD activity and MDA
level by xanthine oxidase and thiobarbituric acid methods,
respectively.Theassay kitswere ofthecommerciallyavailable
grade, and all the operations were carried out following the
instructions of the kit. The ﬁndings were detected using
an ultraviolet/visiblescanning spectrophotometer (Beckman
Coulter, Inc. USA).
2.7. FFA Content in Serum. FFA content in the serum was
determined by colorimetric method after extraction. The
assay kit was of the commercially available grade, and all the
operations were carried out following the instructions of the
kit. The ﬁndings were detected using an ultraviolet/visible
scanning spectrophotometer (Beckman Coulter, Inc. USA).
2.8. Statistical Analysis. Data were expressed as mean ±
standard deviation (SD). The diﬀerence between ISO and
control groups was tested by Student’s t-test, and compar-
isons between all the treated groups and ISO group were
performed using one-way analysis of variance (ANOVA)
with a Dunnetts’ test. Two-tailed values of P<. 05 were
considered to indicate statistical signiﬁcance. All data were
analyzed by using SPSS 11.0 software.
3.Results
3.1. CD40 Expression in Mononuclear Cells. The cell-surface
expression of CD40 in the rat mononuclear cells was
determined using ﬂow cytometry. As is shown in Figure 1,
t h ep e r c e n t a g eo fp o s i t i v ec e l l si nt h eI S Og r o u pi n c r e a s e d
signiﬁcantly, compared with that of the control group (P<
.01). Pre-treatment with BYHWD or CDDP resulted in a
decreased percentage of positive cells. There was a statistical
diﬀerence between the ISO group and the CDDP group and
12.84 and 25.68gkg−1 BYHWD groups (P<. 01).
3.2. CD40 and CD40L Expressions in Tissues. As is shown
in Figure 2, the ISO group presented a high level of CD40
and CD40L expressions, compared with the control group
(P<. 01). Pre-treatment with BYHWD (25.68gkg−1)o r
CDDP showed decreased expressions of CD40 and CD40L.
The ISO group showed a statistical diﬀerence in CD40L
expression (12.84 and 25.68gkg−1 BYHWD groups, P<. 05;
CDDP group, P<. 01), and a signiﬁcant diﬀerence in CD40
expression (25.68gkg−1 BYHWD group and CDDP group,
P<. 01) from the BYHWD and CDDP groups.
3.3. Eﬀect on SOD and MDA in Serum. The results (Table 1)
indicatedthattheISOgroupshowedasigniﬁcantlydecreased
SOD activity (P<. 01) and an increased MDA level (P<
.01) compared with the control group. Pre-treatment with
BYHWD (6.42, 12.84 and 25.68gkg−1) or CDDP increased
the SOD activity, and the SOD activities of BYHWD (6.42,
12.84 and 25.68gkg−1)g r o u p sa n dC D D Pg r o u pw e r e
Table 1: Eﬀect on SOD and MDA in serum.
Group Dose (gkg−1)S O D ( U m L −1)M D A ( n m o l m L −1)
Control — 389.97 ± 17.45 6.37 ± 2.49
ISO — 233.19 ± 26.77∗ 19.25 ± 3.78∗
CDDP 0.073 314.52 ± 21.59∗∗ 11.06 ± 6.19∗∗
BYHWD 25.68 337.08 ± 29.85∗∗ 11.73 ± 4.16∗∗
BYHWD 12.84 334.01 ± 18.74∗∗ 13.66 ± 2.21∗∗
BYHWD 6.42 308.75 ± 33.71∗∗∗ 15.15 ± 3.94∗∗∗
All the data are shown as mean ± SD, n = 10. ∗P<. 01 compared with the
control group; ∗∗P<. 01 and ∗∗∗P<. 05 compared with the ISO group.
markedly higher than that of the ISO group (P<. 05,
P<. 01). On the other hand, BYHWD decreased the MDA
level, and the MDA levels of the three BYHWD groups
(6.42gkg−1, P<. 05; 12.84 and 25.68gkg−1, P<. 01) and
CDDP group (P<. 01) were markedly lower than that of the
ISO group.
3.4. Eﬀect on FFA in Serum. As shown in Figure 3,t h e
content of FFA in the ISO group increased signiﬁcantly (P<
.01), compared with that of the control group. Pre-treatment
with BYHWD decreased the serum content of FFA. The ISO
groupshowed astatistical diﬀerence in the FFAcontent from
the BYHWD groups (25.68gkg−1, P<. 01) and the CDDP
group (P<. 01).
4.Discussion
It is now well accepted that IHD is a multifactorial disease
caused calcium overload, oxidative stress, inﬂammation,
and so forth. It has been found that CD40/CD40L sig-
naling pathway, as an important inﬂammatory regulative
pathway, plays an important role in the process of IHD
[19]. CD40 and CD40L are molecules with prothrombotic
and proinﬂammatory properties, expressed in a variety of
tissues such as immunity cells, vascular wall, and above all,
platelets. CD40L-CD40 interaction may induce inﬂamma-
tory responses that lead to atherosclerosis, plaque destabi-
lization and thrombosis [20]. In the present study, we found
that the ISO-induced myocardial ischemic rats presented a
high level of CD40 and CD40L expressions, compared with
the control group, indicating that myocardial ischemia is
related to CD40/CD40L inﬂammatory pathway. In addition,
other reports have shown that increased co-expression of
CD40/CD40L has been observed in patients with acute
coronary syndrome [21–23], stable coronary artery disease
[24, 25] and acute myocardial infarction [26, 27]. Reversing
of the over-expression of CD40 and/or CD40L by simvas-
tatin and losartan can improve cardiovascular injury [28].
Experimental studies have also shown that the inhibition of
CD40/CD40L pathway not only decreases vascular inﬂam-
mation and prevents the development of atherosclerosis
[29], but also protects ischemic coronary artery in rabbits
[6]. Increasing evidence has indicated that inhibition of
CD40/CD40Lpathway may be anew therapeuticstrategy for
treating IHD. However, Remskar et al. [30]h a v ef o u n dt h a t4 Evidence-Based Complementary and Alternative Medicine
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Figure1:CD40expressioninmononuclearcells(scalebar=100μm).Amyocardialischemicanimalmodelwasestablishedbyadministering
ISO to SD rats. BYHWD was administered in diﬀerent doses (25.68, 12.84 and 6.42gkg−1) to this model. The expressions of CD40 in
mononuclear cells in diﬀerent groups were detected by ﬂow cytometry. Results were expressed as mean ± SD. ##P<. 01, compared with the
control group. ∗∗P<. 01, compared with the ISO group. (a) Control group. (b) ISO group. (c) CDDP group (0.073gkg−1). (d) BYHWD
group (25.68gkg−1). (e) BYHWD group (12.84gkg−1). (f) BYHWD group (6.42gkg−1).
CD40signaling playsa signiﬁcant rolein theinhibitory eﬀect
of T lymphocytes on intimal thickening after arterial injury,
but the mechanism for the increased intimal thickening
in CD40L−/− mice is unclear. In addition, Andreas Zirlik
et al. [31] have demonstrated that CD40 ligand mediates
inﬂammation independently of CD40 by interaction with
Mac-1. Their study has made the surprising ﬁnding that
CD40 does not contribute to CD40L-induced atherogenesis.
These contradictions indicate that many complex problems
need to be solved in the future.
BYHWD is a well-known traditional Chinese medicine
formula made up of seven kinds of Chinese medicine. In
clinic, BYHWD has been widely used for therapy ofischemic
cerebral disease by activating blood circulation and improv-
ing neurological functional recovery [32, 33]. Recently, clini-
cal studieshave found that BYHWD can be used as a therapy
for IHD by relieving angina pectoris, improving myocardial
ischemia and decreasing the volume of myocardial infarc-
tion [34–36]. In the previous study, we have found that
BYHWD can signiﬁcantly inhibit the expression of CD40LEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: CD40 and CD40L expressions in tissues (scale bar =
100μm). A myocardial ischemic animal model was established by
administering ISO to SD rats and BYHWD was administered in
diﬀerent doses (25.68, 12.84 and 6.42gkg−1)t ot h i sm o d e l .B a r
graph (below) showed the CD40 and CD40L densities analyzed by
computer-assisted image quantiﬁcation. Results were expressed as
mean ± SD. ##P<. 01, compared with the control group. ∗P<
.05, ∗∗P<. 01 compared with the ISO group. The ﬁlms (upper)
showed the expressions of CD40 and CD40L in myocardial tissues
of diﬀerent groups detected by western blotting.
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Figure 3: Eﬀect on FFA in serum (scale bar = 100μm). A myocar-
dial ischemic animal model was established by administering ISO
to SD rats and BYHWD was administered in diﬀerent doses (25.68,
12.84 and 6.42gkg−1) to this model. The content of FFA was
detected usingcolorimetricmethod.Resultswereexpressedasmean
± SD. ##P<. 01, compared with the control group. ∗∗P<. 01,
compared with the ISO group.
in myocardial tissues by immunohistochemistry [11]. To
further aﬃrm the eﬀect of BYHWD on the expression of
CD40/CD40L system, we measured the expression of CD40
in the mononuclear cells using ﬂow cytometry and the
expressions of CD40 and CD40L in myocardial tissues by
western blotting. In accordance with the previous results, we
found that BYHWD (25.68 and 12.84gkg−1) reduced the
expression of CD40 in the mononuclear cells and inhibited
the expressions of CD40 and CD40L in myocardial tissues,
which suggests that the roles of BYHWD on myocardial
ischemia may be related to the inhibition of CD40 and
CD40Lexpressions. Inthepreviousstudies,wehavereported
that Tanshinone IIA can suppress the inﬂammation in
atherosclerotic lesion by decreasing the CD40 expression
[18, 37]. Data from the present study suggest that inhibition
of inﬂammatory pathway by decreasing the CD40/CD40L
expression may beoneofthepotential mechanisms by which
BYHWD alleviates IHD. In addition, it has been found that
BYHWD can inhibit the protein and mRNA expressions of
intercellular adhesion molecule-1 and vascular cell adhesion
molecule-1, and restrain inducible nitric oxide synthase
in rats with blood stasis [10, 29, 38]. BYHWD can also
inhibit caspase-1 expression and decrease the production of
inﬂammatory cytokine in middle cerebral artery occlusion
rats[39].Alltheseﬁndings indicatethattherolesofBYHWD
are related to the inhibition of inﬂammation.
As we have known, oxidation plays an important role in
diseases such as atherosclerosis, ischemia/reperfusion injury
and inﬂammation. A large number of oxidative agents can
increase the release of inﬂammatory factors such as TNF-
α,I L - 8a n dN O[ 40]. Antioxidative therapy can inhibit the
production of these inﬂammatory factors [41, 42]. It has
reported that both inﬂammatory markers and oxidation
products increase signiﬁcantly in coronary heart disease and
that there is a positive relationship between oxidation and
coronary heart disease [43] .S O Di sam a j o ra n t i o x i d a t i v e
factor whose activity reﬂects the antioxidative status in
the body, while MDA is a major oxidative product whose
level reﬂects the oxidative stress status in the body. Many
traditional decoctions are recognized as sources of natural
antioxidants that can protect biological system [44]. In
the present study, we found that BYHWD increased the
SOD activity and decreased the MDA level in the serum
of the rat model with ISO-induced myocardial ischemia,
which suggests that the roles of BYHWD on myocardial
ischemia is, to some extent, related to its antioxidative
action.
FFA is a main energy source of myocardium. When
myocardial ischemia occurs, the energy metabolism is dis-
turbedandFFAisaccumulatedabundantlyinthemyocardial
tissues and blood [45–47]. In the present study, our results
shows that the content of FFA in the myocardial ischemic
ratsincreasedsigniﬁcantly,comparedwiththatofthenormal
rats, and thatBYHWDreducedtheFFAcontentintheserum
of myocardial ischemic rats. Previous studies have indicated
that high concentration of FFA can lead to myocardium
injury, dysfunction of the endothelium and atherosclerosis
[48, 49]. Moreover, it has been reported that high con-
centration of FFA is involved in the local inﬂammation6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: The results are summarized in the diagram. The
roles of BYHWD are not only related to its antioxidative action
and regulation of lipid metabolisms, but also to the inhibition
of inﬂammatory pathway by the decreased CD40 and CD40L
expressions in rats with myocardial ischemia.
in myocardial ischemia [50], and that high concentration
of FFA is an independent risk factor for cardiac sudden
death in acute coronary disease [51]. Rectifying the impaired
metabolism of fatty acid may eﬀectively relieve myocardial
ischemia [52]. All these studies suggest that BYHWD has
ap r o t e c t i v ee ﬀect on myocardial ischemia by rectifying
impaired metabolism of FFA in rats.
In conclusion, the present study shows that BYHWD
has a protective eﬀect against ISO-induced myocardial
ischemia, and this eﬀect may be attributed to the down-
regulation of CD40 and CD40L expressions. Moreover, the
roles of BYHWD are related to the antioxidative activity
and regulation of lipid metabolisms. These results are
summarized in Figure 4. Our results provide an explanation
for the relationship between the anti-inﬂammation and
the protective eﬀect of BYHWD on myocardial ischemia.
The ﬁndings of the present study may shed light on the
pharmacological basis for the clinical application of the
traditional Chinese medicine in the treatment of ischemic
cardiovascular diseases.
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